Delivery Order SPE2DB22D9207-SPE2DB25FH5DS
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 300 mg/2 ml auto-injector prefilled syringes. The contract, valued at $6,848.92 with a firm fixed-price structure, was awarded on August 13, 2025, with an ultimate completion date of September 4, 2025. This delivery order carries no set-aside designation and will be performed at the company's Park...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $17,122.20 by the Defense Logistics Agency on August 1, 2025, for the supply of Xolair 150 mg/ml auto-injectors. The award is issued under a firm fixed-price contract structure with an ultimate completion date of August 22, 2025, and represents no set-aside designation. This delivery order draws from DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $37,137.60 by the Defense Logistics Agency (DLA) on August 21, 2025. The delivery order, which carries no set-aside designation, is for Xolair 150 mg/ml syringes with an ultimate completion date of September 12, 2025. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $28.3K by the Defense Logistics Agency's Medical Supply Chain on August 27, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order is scheduled for completion by September 18, 2025, with no set-aside designation applied. The award represents a discrete fulfillment under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 14, 2025, for the supply of Xolair 300 mg/2 mL syringes. The contract is valued at $3,720.96 and is structured as a firm fixed-price delivery order with an ultimate completion date of September 5, 2025. This award was made without a set-aside designation, allowing the vendor to compete on the open...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,094.80 by the Defense Logistics Agency on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...
- The U.S. government's Defense Logistics Agency (DLA) has awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the purchase of Xolair 150 mg/mL auto-injectors, with a ceiling value of $20,546.64. This delivery order is part of a larger single-award indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,424.44 by the Defense Logistics Agency (DLA) on August 7, 2025, for the supply of XOLAIR 150 mg/ml autoinjector medication. The contract carries a firm fixed-price structure with an ultimate completion date of August 28, 2025, and was awarded without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $2,321.10 by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract, awarded without set-aside designation, carries a firm fixed-price structure with an ultimate completion date of September 18, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at approximately $142,000 by the Defense Logistics Agency (DLA) for XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 16, 2025, and was awarded on August 25, 2025, without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery...
- SPE2DB22D9207Indefinite Delivery Contract
- SPE2DB22D9207-SPE2DB25FH5DSDelivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 20, 2025, for the supply of Xolair 300 mg/2 ml auto-injector vials. The contract has a ceiling value of $85,611.50 with an ultimate completion date of September 11, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.9 billion contract vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products to support Department of Defense healthcare facilities worldwide. Xolair (omalizumab) is a monoclonal antibody used to treat moderate to severe allergic asthma and chronic idiopathic urticaria, making this delivery order part of the DLA's broader pharmaceutical supply chain supporting military health services. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical procurement ecosystem, leveraging its woman-owned small business status and its substantial IDC with the DLA to consistently compete for and secure contracts covering diverse medical products, from specialty biologics to routine medications and medical consumables distributed to military treatment facilities across the Department of Defense.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $85.6k | 8/20/25 |